The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. (Q35181440)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. (English)

1 reference

Europe PubMed Central

7 August 2017

author name string

Erika J Schneble

1

1 reference

Europe PubMed Central

7 August 2017

John S Berry

2

1 reference

Europe PubMed Central

7 August 2017

Francois A Trappey

3

1 reference

Europe PubMed Central

7 August 2017

Guy T Clifton

4

1 reference

Europe PubMed Central

7 August 2017

Sathibalan Ponniah

5

1 reference

Europe PubMed Central

7 August 2017

Elizabeth Mittendorf

6

1 reference

Europe PubMed Central

7 August 2017

George E Peoples

7

1 reference

Europe PubMed Central

7 August 2017

publication date

1 January 2014

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

6

1 reference

Europe PubMed Central

7 August 2017

5

1 reference

Europe PubMed Central

7 August 2017

519-531

1 reference

Europe PubMed Central

7 August 2017

Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

The E75 HER2/neu peptide vaccine

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Monitoring immune responses in cancer patients receiving tumor vaccines

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Victories and deceptions in tumor immunology: Stimuvax(®)

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Regulatory T cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Prospective study of electrical impedance scanning for identifying young women at risk for breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.22

21 January 2018

Identifiers

10.2217/IMT.14.22

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35181440&oldid=1966988978"